Genmab announces top-line phase II results for ofatumumab
Genmab A/S announced top-line results from a Phase II study of ofatumumab in combination with salvage chemotherapy to treat relapsed or refractory aggressive lymphoma, including diffuse large B-cell lymphoma (DLBCL).
A total of 61 patients with aggressive lymphoma, who had persistent or progressive disease after first-line treatment with rituximab combined with chemotherapy, were treated in the study. The overall response rate (ORR) was 61%. There were no unexpected safety findings. The most common grade 3 or higher adverse events were thrombocytopenia (59% of pts), anemia (36%), neutropenia (26%), lymphopenia (23%), leukopenia (18%), febrile neutropenia (13%) and hypokalemia (13%).
About the study
Patients in the study had previously received first line treatment with rituximab combined with standard chemotherapy. Patients received three cycles of ofatumumab in combination with ICE or DHAP salvage chemotherapy, which is used when cancer recurs or does not respond to first line treatment. The primary objective of the study was to evaluate the overall response rate of patients to ofatumumab in combination with ICE or DHAP chemotherapy according to criteria recognized by regulatory authorities known as the Revised Response Criteria for Malignant Lymphoma.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.